FDA says anemia drug peginesatide is comparable to other treatments

12/5/2011 | Reuters

FDA drug reviewers said Affymax's peginesatide, a treatment for anemia in dialysis patients with chronic kidney disease, performs comparably with Amgen's Epogen and Aranesp in maintaining an ideal hemoglobin level. However, reviewers voiced concern about peginesatide's safety profile. An FDA panel is set to review the drug Wednesday, and the agency's final decision is anticipated by March 27.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI